People · Operator
Named in public records as an officer, director or promoter · active 2008–2021 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Portola Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $158.1M | $315.8M | 2008 |
| Cyteir Therapeutics, Inc. | — | Biotechnology | Series C | $111.9M | $2.6B | 2018 |
| Calithera Biosciences, Inc. | — | Biotechnology | Series B | $67.1M | $635.0M | 2010 |
| Thrasos Innovation Inc. | — | Biotechnology | Series A | $14.0M | $506.1M | 2015 |
| Hydra Biosciences Inc | — | Biotechnology | Series A | $10.5M | $379.9M | 2015 |
| Gemini Therapeutics, Inc. | — | Biotechnology | Seed | $2.0M | $88.8M | 2016 |
Jean George at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jean George on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| James Topper | 1 | 12 |
| Russell Hirsch | 1 | 10 |
| Jens Eckstein | 1 | 8 |
| JEFF BIRD | 1 | 7 |
| Nicholas Galakatos | 1 | 6 |
| JOSEPH S. ZAKRZEWSKI | 1 | 6 |
| Joseph Zakrzewski | 1 | 6 |
| Ralph E. Christoffersen | 1 | 6 |
| Robert Carpenter | 1 | 5 |
| Farah Champsi | 1 | 5 |
| Ralph Christoffersen | 1 | 5 |
| Alan Frazier | 1 | 5 |
| Karen Hong | 1 | 4 |
| James Wells | 1 | 4 |
| Kevin Mills | 1 | 4 |
| Steven E. Hall | 1 | 4 |
| Charles Homcy | 1 | 4 |
| Tom Burke | 1 | 3 |
| Paul Goldenheim | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.